CareCloud (CCLD) Profitability Turn Challenges Dilution Focus After FY 2025 Earnings

CareCloud (CCLD) has capped FY 2025 with fourth quarter revenue of US$34.4 million and basic EPS of US$0.04, alongside trailing 12 month revenue of US$120.5 million and basic EPS of US$0.10, marking a clean move away from the losses seen earlier in the period. The company has seen quarterly revenue step up from US$27.4 million in Q2 2025 to US$34.4 million in Q4 2025, while quarterly basic EPS has shifted from a loss of US$0.04 in Q1 2025 to positive readings in each subsequent quarter, pointing to firmer profitability. With earnings now in the black and margins heading in a positive direction, the latest print frames an earnings story that increasingly centers on how durable this profitability may be.

See our full analysis for CareCloud.

With the headline results on the table, the next step is to see how these numbers line up against the big narratives around CareCloud, separating what is backed by the data from what may need a rethink.

See what the community is saying about CareCloud

Profitability Shift Shows Up In TTM Numbers

• On a trailing 12 month basis, CareCloud moved from a loss of US$4.5 million in Q4 2024 to net income of US$3.9 million in Q4 2025, with trailing basic EPS moving from a loss of US$0.28 to a profit of US$0.10 over the same window.
• Bulls argue that this move into the black and the expected 47.7% annual earnings growth point to a business with improving economics. However, the step up from quarterly net income of US$0.01 million in Q4 2024 to US$1.5 million in Q4 2025 also means any slowdown in that pace would directly test how realistic those bullish growth assumptions really are.
  • Supporters highlight that trailing revenue rose from US$110.8 million to US$120.5 million while margins improved enough to swing to a US$3.9 million profit, which lines up with the idea of better earnings quality.
  • At the same time, the fact that quarterly net income over FY 2025 sits in a fairly tight band between about US$1.5 million and US$1.7 million suggests investors may want to watch whether earnings keep climbing or just hold around current levels.

CareCloud's recent turn to profitability and the expectations for fast earnings growth are exactly what bullish investors focus on, so this set of results is a useful starting point if you want to test that upside story against the numbers. 🐂 CareCloud Bull Case

P/E Of 31.7x And DCF Gap To US$16.88

• The shares are reported to trade on a trailing P/E of 31.7x at a price of US$2.91, compared with a P/E of 38x for peers and 29.3x for the wider Global Healthcare Services group, while a DCF fair value of US$16.88 sits well above the current share price.
• Consensus narrative flags this mix of metrics as a tension. A P/E that is lower than peers but slightly higher than the broader industry sits alongside a DCF fair value that is very far above US$2.91, so investors are left weighing whether the recent shift to US$3.9 million of trailing net income is enough to justify the gap to US$16.88.
  • On one side, the move from trailing losses of US$4.5 million to profits of US$3.9 million fits the idea that earnings quality has improved, which can help explain why the stock does not trade at a deep discount to the industry multiple.
  • On the other, the modest 8.3% revenue growth rate being below the 10.4% US market forecast gives cautious investors a concrete reason to question whether the large distance between US$2.91 and the DCF fair value can close quickly.

Dilution Risk Against 47.7% Earnings Growth Forecast

• Trailing earnings are expected to grow about 47.7% per year while revenue growth is put at 8.3% per year, and analysts also expect shares outstanding to rise by about 7% per year after a year in which shareholders already saw substantial dilution.
• Bears focus on that dilution and on slower revenue growth than the wider US market, arguing that even with quarterly net income stabilizing in the US$1.5 million to US$1.7 million range in FY 2025, ongoing issuance of new shares and below market 8.3% revenue growth could limit how much of the forecast earnings expansion actually translates into per share value for existing holders.
  • The history of substantial dilution in the last 12 months, combined with expectations of further 7% annual growth in share count, gives that cautious view a clear footing in the data rather than being only theoretical.
  • At the same time, the move from a trailing net loss of US$4.5 million to a profit of US$3.9 million shows the core business generated enough improvement to offset past dilution in the short term, which is why some investors see FY 2025 as a test of whether that progress can keep up with any future share issuance.

Skeptical investors often

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CareCloud on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Curious how this mix of progress and caution fits together? Take a closer look at the numbers now and weigh the 3 key rewards and 1 important warning sign against your own view.

Explore Alternatives

CareCloud's reliance on heavy earnings growth forecasts alongside slower 8.3% revenue growth, ongoing dilution and a high 31.7x P/E ratio makes future value creation less certain for some investors.

If that mix of dilution risk and rich expectations feels a bit tight for comfort, you might want to scan our 68 resilient stocks with low risk scores to find businesses where earnings quality and balance sheet strength are already doing more of the heavy lifting.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.